Budesonide/formoterol single inhaler therapy is well tolerated and reduces systemic steroid use

R. Scicchitano, M. Palmqvist, A. Andersson, K. Rabe (Adelaide, Australia; Gothenburg, Lund, Sweden; Leiden, The Netherlands)

Source: Annual Congress 2004 - Primary care: asthma treatments
Session: Primary care: asthma treatments
Session type: Thematic Poster Session
Number: 1986
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Scicchitano, M. Palmqvist, A. Andersson, K. Rabe (Adelaide, Australia; Gothenburg, Lund, Sweden; Leiden, The Netherlands). Budesonide/formoterol single inhaler therapy is well tolerated and reduces systemic steroid use. Eur Respir J 2004; 24: Suppl. 48, 1986

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003

Budesonide/formoterol single inhaler therapy reduces overreliance on rapid-acting reliever medication
Source: Eur Respir J 2004; 24: Suppl. 48, 344s
Year: 2004

Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
Source: ERJ Open Res 2016: 00106-2015
Year: 2016



Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007


Steroid inhaler dose reduction in comparison with montelukast discontinuation in asthma patients controlled by steroid inhaler and montelukast
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018

Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy
Source: Annual Congress 2010 - Management of airway disease
Year: 2010

Budesonide/formoterol maintenance and reliever therapy – effective treatment at a lower cost
Source: Annual Congress 2008 - Rationale of self-education in asthma therapy
Year: 2008

Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy
Source: Eur Respir J 2010; 36: 524-530
Year: 2010



Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009


Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Budesonide/formoterol in a single inhaler improves asthma control more effectively than a higher dose of fluticasone
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Budesonide/formoterol maintenance and reliever therapy at two different maintenance doses
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Fluticasone propionate/formoterol fumarate combination therapy is equally effective and well-tolerated when administered with or without a spacer device to patients with asthma
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 159s
Year: 2001

Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Budesonide and formoterol in a single inhaler is safe and effective in the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 159s
Year: 2001